Safety, Tolerability, and Preliminary Efficacy Study of ALS-357 in Patients With Cutaneous Metastatic Melanoma

A phase I trial to evaluate the safety and tolerability of ALS-357 when administered for four weeks as a topical ointment, in escalating doses, to patients with cutaneous metastatic melanoma and to evaluate the effect of escalating doses of topically applied ALS-357 on histological remission of cutaneous metastatic melanoma and induction of apoptotic biomarkers.

Additional locations may be listed on ClinicalTrials.gov for NCT00701987.

See trial information on ClinicalTrials.gov for a list of participating sites.

Trial PhasePhase I

Trial Typetreatment

Lead OrganizationAdvanced Life Sciences

• Primary IDALS-357-001
• Secondary IDsNCI-2010-01853
• ClinicalTrials.gov IDNCT00701987